Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Roche to present data from one of -3-

05/11/2021 | 01:01am EDT
Cotellic(R)(cobimetinib); Erivedge(R)(vismodegib); 
Gavreto(R)(pralsetinib); Gazyva(R)/Gazyvaro(R)(obinutuzumab); 
Herceptin(R)(trastuzumab); Kadcyla(R)(trastuzumab emtansine); 
MabThera(R)/Rituxan(R)(rituximab); Perjeta(R)(pertuzumab); 
Polivy(R)(polatuzumab vedotin); Tarceva(R)(erlotinib); 
Rozlytrek(R)(entrectinib); Tecentriq(R)(atezolizumab); 
Venclexta(R)/Venclyxto(R)(venetoclax) in collaboration with AbbVie; 
Xeloda(R)(capecitabine); Zelboraf(R)(vemurafenib). Furthermore, the 
Roche Group has a robust investigational oncology pipeline focusing on 
new therapeutic targets and novel combination strategies. For more 
information on Roche's approach to cancer, visit 
   About Roche 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
   All trademarks used or mentioned in this release are protected by law. 
   Roche Group Media Relations 
   Phone: +41 61 688 8888 / e-mail: media.relations@roche.com 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
   -- 11052021_MR_ASCO 2021 Curtain Raiser 

(END) Dow Jones Newswires

May 11, 2021 01:00 ET (05:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. -1.55% 113.12 Delayed Quote.5.57%
CHUGAI PHARMACEUTICAL CO., LTD. -2.21% 4250 End-of-day quote.-22.77%
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
PATIENT ACCESS SOLUTIONS, INC. -1.64% 0.006 Delayed Quote.-70.00%
ROCHE HOLDING AG -0.04% 348.25 Delayed Quote.12.70%
All news about ROCHE HOLDING AG
06/18Ahead of pivotal AGM, Toshiba board chairman vows to be 'agent of positive ch..
06/17ROCHE HOLDINGS AGá : Deutsche Bank reiterates its Neutral rating
06/17Synlogic, Roche in Bowel-Disease Collaboration
06/17ROCHEá : Syncona CFO to Retire; Three New Executives Named
06/17ROCHEá : Check You Employment Agreement's Restrictive Covenant
06/16WALL STREET STOCK EXCHANGE : How yesterday’s data could affect Fed policy
06/16Atea Pharma Hits Development Milestone for Covid-19 Treatment
06/16ROCHEá : Atea Pharmaceuticals Announces Achievement of AT-527 Development Milest..
06/16ROCHEá : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage T..
06/15ELOXX PHARMACEUTICALSá : Roche Discloses 5.3% Stake in Eloxx Pharmaceuticals
More news
Sales 2021 60 592 M 65 621 M 65 621 M
Net income 2021 14 612 M 15 825 M 15 825 M
Net cash 2021 4 915 M 5 323 M 5 323 M
P/E ratio 2021 20,3x
Yield 2021 2,69%
Capitalization 301 B 326 B 325 B
EV / Sales 2021 4,88x
EV / Sales 2022 4,74x
Nbr of Employees 101 465
Free-Float 83,4%
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 355,40 CHF
Last Close Price 348,25 CHF
Spread / Highest target 25,8%
Spread / Average Target 2,05%
Spread / Lowest Target -16,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG12.70%325 803
JOHNSON & JOHNSON2.92%426 557
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795